Melanoma brain metastases: correlation of imaging features with genomic markers and patient survival
- 7 November 2016
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 131 (2) , 341-348
Abstract
Purpose To identify MR imaging features of melanoma brain metastases (MBM) that correlate with genetic profile of melanoma and patient survival. Materials and methods Patients with newly diagnosed melanoma metastases were identified from institutional database A retrospective review of brain MRI was performed focusing on lesion number, size, T1-, T2- and diffusion-weighted signal characteristics, hemorrhage, necrosis, enhancement pattern and edema. Genomic (BRAF status), treatment and survival data was collected. Results 98 patients were included in final analysis. A strong correlation was found between size of the largest lesion and the percent of lesions with T1-weighted hyperintense signal (R = 0.49), percent of lesions with size >1 cm (0.55), and the lesions that are clearly hemorrhagic (0.43). The analyzed imaging parameters were found to be independent of BRAF mutation status. The median survival of subjects with single lesion (9.1 months) was significantly higher than the median survival of subjects with more than 1 lesion (4.9 months) (p = 0.002). Patients with 2–18 lesions had significantly longer survival (5.6 months) than with >18 lesions (2 months) (p < 0.001). Other imaging parameters such as lesion size, T1-weighted hyperintensity, number of lesions with edema and hemorrhage were not found to be significantly related to survival. BRAF inhibitor treatment was found to be the most significant prognostic factor (p = 0.002) among patients with multiple lesions. Conclusion There is a statistically significant correlation between number of brain metastases and survival. In patients with multiple lesions, BRAF inhibitor treatment was the most significant prognostic factor.Keywords
This publication has 23 references indexed in Scilit:
- Combining magnetic resonance spectroscopy and molecular genomics offers better accuracy in brain tumor typing and prediction of survival than either methodology aloneInternational Journal of Oncology, 2011
- Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post‐brain metastases survivalCancer, 2010
- Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanomaCancer, 2010
- Prognostic factors for survival in melanoma patients with brain metastasesCancer, 2010
- Brain and leptomeningeal metastases from cutaneous melanoma: Survival outcomes based on clinical featuresNeuro-Oncology, 2008
- Unbiased Recursive Partitioning: A Conditional Inference FrameworkJournal of Computational and Graphical Statistics, 2006
- Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance SystemJournal of Clinical Oncology, 2004
- Determinants of Outcome in Melanoma Patients With Cerebral MetastasesJournal of Clinical Oncology, 2004
- Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanomaCancer, 2002
- Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanomaJournal of Neurosurgery, 1998